Adalimumab (Humira) is an inhibitor of tumor necrosis factor alpha. It binds specifically to TNF and neutralizes its biological function by blocking its interaction with p55 and p75 cell surface TNF receptors.
The use of adalimumab in diseases is recommended as active rheumatoid arthritis, juvenile incidence plaques, ankylosing spondylitis, psoriatic arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, uveitis, hidradenitis suppurativa.
Adalimumab is contraindicated with hypersensitivity, active tuberculosis, heart failure, renal failure, liver failure and serious infections.
The use of adalimumab is not recommended during pregnancy, lactation or alcohol consumption.
Adalimumab can have side effects such as pain in the head, vomiting, nausea, sinusitis and respiratory infections.
Adalimumab is marketed in the United States under the name:
HUMIRA PEN solution for injection 40 mg / 0.8 ml
HUMIRA JERINGA solution for injection 10 mg / 0.2 ml
HUMIRA JERINGA solution for injection 20 mg / 0.4 ml
HUMIRA JERINGA solution for injection 40 mg / 0.8 ml
HUMIRA VIAL solution for injection 40 mg / 0.8 ml
Video credits to Medicines/Diseases YouTube channel